{"schema_version":"secwatch.filing_event.v1","accession":"0001628280-25-036846","form_type":"8-K","ticker":"CBIO","cik":"0001253689","company_name":"CRESCENT BIOPHARMA, INC.","filed_at":"2025-07-31T23:59:59+00:00","discovered_at":"2026-05-14T18:02:43.534324+00:00","generated_at":"2026-05-17T22:10:48.123648+00:00","sec_items":["2.02","5.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.85,"confidence":"high","headline":"Crescent Biopharma Q2 net loss $21.8M; merger & $200M financing closed","bullets":["Net loss $21.8M ($4.93/share) for Q2 2025; R&D $12.1M, G&A $8.9M.","Cash $152.6M as of June 30, 2025, expected to fund operations through 2027.","Completed merger with GlycoMimetics and closed $200M private financing.","IND for CR-001 (PD-1 x VEGF bispecific) on track for Q4 2025; proof-of-concept data H2 2026.","Adopted Executive Severance Plan with change-in-control benefits for executives."],"urls":{"canonical":"https://secwatch.observer/filing/0001628280-25-036846","json":"https://secwatch.observer/filing/0001628280-25-036846.json","markdown":"https://secwatch.observer/filing/0001628280-25-036846.md","text":"https://secwatch.observer/filing/0001628280-25-036846.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1253689/000162828025036846/0001628280-25-036846-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1253689/000162828025036846/cbio-20250729.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-17T22:10:48.123648+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}